John N. Allan, MD, discusses data for fixed-duration regimens in chronic lymphocytic leukemia and their respective nuances.
Back
Optimizing Fixed-Duration Approaches in Chronic Lymphocytic Leukemia
John N. Allan, MD, outlines the need for improved fixed-duration treatment approaches in high-risk CLL.
Optimizing Fixed-Duration Approaches in Chronic Lymphocytic Leukemia
Episodes
All
All
John N. Allan, MD, discusses all things regarding fixed-duration regimens in CLL from a review of the most pivotal data for the topic.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/30
5